Intracranial Efficacy of Pyrotinib and Capecitabine Combination Therapy in HER2-Positive Breast Cancer with Brain Metastases

References

• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41(22):3867–3872. doi:10.1200/jco.22.02864
   PubMed Web of Science ®Google Scholar
• Corti C, Antonarelli G, Criscitiello C, et al. Targeting brain metastases in breast cancer. Cancer Treat Rev. 2022;103:102324. doi:10.1016/j.ctrv.2021.102324
   PubMed Web of Science ®Google Scholar
• Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers. 2021;13(12):2927.
   PubMed Web of Science ®Google Scholar
• Zimmer AS, Van Swearingen AED, Anders CK. HER2-positive breast cancer brain metastasis: a new and exciting landscape. Cancer Rep. 2022;5(4):e1274. doi:10.1002/cnr2.1274
   Google Scholar
• Lee J, Park YH. Trastuzumab deruxtecan for HER2+ advanced breast cancer. Future Oncol. 2022;18(1):7–19. doi:10.2217/fon-2021-0550
   PubMed Web of Science ®Google Scholar
• Meric-Bernstam F, Johnson AM, Dumbrava EEI, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25(7):2033–2041. doi:10.1158/1078-0432.ccr-18-2275
   PubMed Web of Science ®Google Scholar
• Xuhong JC, Qi XW, Zhang Y, et al. Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. Am J Cancer Res. 2019;9(10):2103–2119.
   PubMed Web of Science ®Google Scholar
• Takada M, Toi M. Neoadjuvant treatment for HER2-positive breast cancer. Chin Clin Oncol. 2020;9(3):32. doi:10.21037/cco-20-123
   PubMed Web of Science ®Google Scholar
• Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48. doi:10.1038/s41571-019-0268-3
   PubMed Web of Science ®Google Scholar
• Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475–1495. doi:10.1016/j.annonc.2021.09.019
   PubMed Web of Science ®Google Scholar
• Ivanova M, Porta FM, Giugliano F, et al. Breast cancer with brain metastasis: molecular insights and clinical management. Genes. 2023;14(6):1160.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Miles D, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–1121. doi:10.1093/annonc/mdu133
   PubMed Web of Science ®Google Scholar
• Krop IE, Lin NU, Blackwell K, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113–119. doi:10.1093/annonc/mdu486
   PubMed Web of Science ®Google Scholar
• Montemurro F, Delaloge S, Barrios CH, et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial(☆). Ann Oncol. 2020;31(10):1350–1358. doi:10.1016/j.annonc.2020.06.020
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Park YH, Yamashita T, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. Cancer Discov. 2022;12(12):2754–2762. doi:10.1158/2159-8290.cd-22-0837
   PubMed Web of Science ®Google Scholar
• Lin NU, Borges V, Anders C, et al. Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial. J Clin Oncol. 2020;38(23):2610–2619. doi:10.1200/jco.20.00775
   PubMed Web of Science ®Google Scholar
• Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase 2 study. Lancet Oncol. 2013;14(1):64–71. doi:10.1016/s1470-2045(12)70432-1
   PubMed Web of Science ®Google Scholar
• Freedman RA, Gelman RS, Anders CK, et al. TBCRC 022: a Phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 2019;37(13):1081–1089. doi:10.1200/jco.18.01511
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li L, Zhang G, et al. Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1033–1034:117–127. doi:10.1016/j.jchromb.2016.08.009
   PubMed Web of Science ®Google Scholar
• Ma F, Ouyang Q, Li W, et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and/or trastuzumab: a randomized, Phase II Study. J Clin Oncol. 2019;37(29):2610–2619. doi:10.1200/jco.19.00108
   PubMed Web of Science ®Google Scholar
• Fecci PE, Champion CD, Hoj J, et al. The evolving modern management of brain metastasis. Clin Cancer Res. 2019;25(22):6570–6580. doi:10.1158/1078-0432.ccr-18-1624
   PubMed Web of Science ®Google Scholar
• Xiao W, Zheng S, Yang A, et al. Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study. Cancer Manag Res. 2018;10:5329–5338. doi:10.2147/cmar.s176763
   PubMed Web of Science ®Google Scholar
• Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. Lancet Oncol. 2022;23(3):353–361. doi:10.1016/s1470-2045(21)00716-6
   PubMed Web of Science ®Google Scholar
• Miller JA, Kotecha R, Ahluwalia MS, et al. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer. 2017;123(12):2283–2293. doi:10.1002/cncr.30616
   PubMed Web of Science ®Google Scholar
• Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 2022;33(3):321–329. doi:10.1016/j.annonc.2021.12.005
   PubMed Web of Science ®Google Scholar
• Lange M, Joly F, Vardy J, et al. Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol. 2019;30(12):1925–1940. doi:10.1093/annonc/mdz410
   PubMed Web of Science ®Google Scholar
• Koevoets EW, Schagen SB, de Ruiter MB, et al. Effect of physical exercise on cognitive function after chemotherapy in patients with breast cancer: a randomized controlled trial (PAM study). Breast Cancer Res. 2022;24(1):36. doi:10.1186/s13058-022-01530-2
   PubMed Web of Science ®Google Scholar
• Bartsch R, Berghoff AS, Furtner J, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–1847. doi:10.1038/s41591-022-01935-8
   PubMed Web of Science ®Google Scholar
• Saura C, Oliveira M, Feng YH, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Phase III NALA trial. J Clin Oncol. 2020;38(27):3138–3149. doi:10.1200/jco.20.00147
   PubMed Web of Science ®Google Scholar
• Xu B, Yan M, Ma F, et al. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, Phase 3 trial. Lancet Oncol. 2021;22(3):351–360. doi:10.1016/s1470-2045(20)30702-6
   PubMed Web of Science ®Google Scholar